Diagnostic criteria of pancreatic pathology.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16696-e16696
Author(s):  
Irina V. Neskubina ◽  
Elena M. Frantsiyants ◽  
Irina V. Kaplieva ◽  
Ekaterina I. Surikova ◽  
Valeria A. Bandovkina ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Chronic Pancreatitis ◽  
Pancreatic Adenocarcinoma ◽  
Neuroendocrine Tumors ◽  
Malignant Tumors ◽  
Lymphatic Vessels ◽  
Blood Levels ◽  
Pancreatic Neuroendocrine Tumors ◽  
Pancreatic Pathology ◽  
Diagnostic Criterion

e16696 Background: Vascular endothelial growth factors (VEGF) and their receptors provide malignant tumors with new blood and lymphatic vessels. However, it is unknown whether their level in the blood can help to determine the tumor nature or to distinguish malignant pathology from chronic organ inflammation. The purpose of the study was to reveal the dynamics of VEGF in the blood of patients with chronic pancreatitis and pancreatic cancer. Methods: The study included male patients with chronic pancreatitis (n = 9), pancreatic adenocarcinoma T1-3N0-1M0 (n = 10) and pancreatic neuroendocrine tumors T1-3N0-1M0 (n = 12) before treatment. Healthy males (n = 21) were controls. Blood levels of VEGF-A, VEGF-C, VEGF-R1 and VEGF-R3 were determined by ELISA using standard test systems (Cusabio, China). Results: VEGF-A in the blood of patients with pancreatic cancer increased: in adenocarcinoma by 2.6 times, in neuroendocrine tumors by 1.7 times (p < 0.05), while chronic pancreatitis was characterized with reduced VEGF-A in the blood – 2.2 times lower than in healthy people. Serum concentration of VEGF-C increased only in patients with adenocarcinoma – 1.3 times higher than the norm (p < 0.05). The amount of VEGF-R1 and VEGF-R3 receptors increased in the blood of patients with chronic pancreatitis (by 2.2 and 1.6 times respectively, p < 0.05) and pancreatic neuroendocrine tumors (2.2 and 1.3 times, p < 0.05). Conclusions: The rise of VEGF-A in the blood is a sign of malignant pancreatic pathology; its combination with the accumulation of VEGF-C in the blood is a diagnostic criterion for pancreatic adenocarcinoma, and a combination with an increase in VEGF-R1 and VEGF-R3 is a diagnostic criterion for pancreatic neuroendocrine tumors. In contrast, chronic pancreatitis is characterized by reduced VEGF-A together with the increase in both types of receptors in the blood.

scholarly journals New data on the immunohistochemical and morphological characteristics of ductal pancreatic adenocarcinoma

2018 ◽  
Vol 42 (4) ◽  
pp. 47-52
Author(s):  
Y. Y. Rakina ◽  
M. V. Zav’yalova ◽  
N. V. Krakhmal ◽  
A. P. Koshel ◽  
S. G. Afanasyev ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Pancreatic Adenocarcinoma ◽  
Malignant Tumors ◽  
Standard Procedure ◽  
Morphological Characteristics ◽  
Developed Countries ◽  
Ductal Pancreatic Adenocarcinoma ◽  
Microscopic Features ◽  
Giovanni Battista Morgagni ◽  
Immunohistochemical Studies

In recent years, especially in developed countries, there has been an increase in the incidence of pancreatic cancer. Only 20% of tumors at the time of diagnosis are evaluated as resectable, but in these cases, the prognosis of the disease is unfavorable. The overall 5-year survival rate does not exceed 5%. Pancreatic cancer was described in the 1760s by Giovanni Battista Morgagni in his classic book “De Sedibus et Causis Morborum per Anatomen Indigatis”. Over the next 200 years, pathologists significantly improved our understanding of the macro- and microscopic features of this disease. At the same time, morphological research remained the basis of diagnostics for centuries. The introduction of immunohistochemical studies into clinical practice in the late 1970s and early 1980s radically changed our approach to diagnosing this disease. Evaluation of morphological features, as well as features of expression of markers that determine the invasive potential of such neoplasms, can serve in the future as a fundamental basis in solving questions concerning possible factors of prognosis upon malignant tumors of such a localization. Aim of research — to study the morphological and immunohistochemical features of ductal pancreatic adenocarcinoma. Materials and methods. The study included 84 patients with pancreatic cancer T1-4N0-2M0-1 stage, aged from 37 to 83, who underwent surgical treatment. Morphological study of the operating material was carried out. The condition for inclusion in the study was a histotype of the tumor, namely ductal pancreatic adenocarcinoma. Posting of the material, preparation of histological preparations, coloring, immunohistochemical examination were carried out according to a standard procedure. Results and conclusion. The study made it possible to characterize the tumor morphology, as well as the features of expression of markers associated with more evident invasive characteristics of the tumor. The results of this work may be of interest in terms of their further comparison with the parameters of various forms of progression upon pancreatic cancer.

Application of the Pancreatic Adenocarcinoma Staging System to Pancreatic Neuroendocrine Tumors

2007 ◽  
Vol 205 (4) ◽  
pp. 558-563 ◽  
Author(s):  
Karl Y. Bilimoria ◽  
David J. Bentrem ◽  
Ryan P. Merkow ◽  
James S. Tomlinson ◽  
Andrew K. Stewart ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Neuroendocrine Tumors ◽  
Staging System ◽  
Pancreatic Neuroendocrine Tumors

scholarly journals CFTR F508del mutation and 5T allele in patients with chronic pancreatitis and pancreatic adenocarcinoma

2011 ◽  
Vol 58 (3) ◽  
pp. 43-47
Author(s):  
Aleksandra Nikolic ◽  
Jelena Dinic ◽  
Dragica Radojkovic ◽  
Snezana Lukic ◽  
Dragan Popovic ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Chronic Pancreatitis ◽  
Pancreatic Adenocarcinoma ◽  
Genetic Variants ◽  
Cftr Gene ◽  
Common Mutation ◽  
Healthy Individuals ◽  
Pancreatic Diseases ◽  
Pancreatic Disorders ◽  
Pancreatic Pathology

Introduction: Mutations in the CFTR gene may be associated with various types of pancreatic pathology and result in higher risk of pancreatic disorders. While delta F508 is the most common mutation in cystic fibrosis patients, the allel 5T is associated with atypical forms of cystic fibrosis. Study aim: The aim of this study was to establish the frequencies of F508del mutation and 5T allele in the CFTR gene in patients with chronic pancreatitis and pancreatic cancer, as well as to investigate whether these genetic variants represent risk factors for pancreatic diseases. Study methods: The study has encompassed 50 patients with chronic pancreatitis and 50 patients with pancreatic adenocarcinoma, as well as 124 healthy individuals. The analysis of F508del mutation and alleles 5T, 7T and 9T of the polythymidine tract was performed on DNA extracted from periferal blood by PCR-mediated site-direted mutagenesis (PSM) method. Results: The frequency of F508del mutation in the group of patients with chronic pancreatitis (3.0%) was significantly increased (p=0.032) in comparison to the group of healthy individuals (0.4%), while other analyzed differences were not statistically significant. Conclusion: The results of this study indicate that F508del mutation in the CFTR gene respresents a risk factor for the development of chronic pancreatitis.

scholarly journals Follow-up of patients with pseudotumoral chronic pancreatitis: outcome and surveillance

2018 ◽  
Vol 40 (2) ◽  
pp. 29-35
Author(s):  
F. I. Téllez-Âvila ◽  
Â. Villalobos-Garita ◽  
M. Giovannini ◽  
C. Chan ◽  
J. Hernandez-Calleros ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Chronic Pancreatitis ◽  
Pancreatic Adenocarcinoma ◽  
Endoscopic Ultrasound ◽  
Needle Aspiration ◽  
Fine Needle ◽  
Surveillance Interval ◽  
Mass Lesions ◽  
Space Occupying Lesion

Aim: to follow up patients with pseudotumoral chronic pancreatitis (PCP) to assess their outcome and identify an optimal surveillance interval. Methods: data obtained prospectively were analyzed in a retrospective manner. Patients with clinical evidence of chronic pancreatitis (abdominal pain in the epigastrium, steatorrhea, and diabetes mellitus), endoscopic ultrasound (EUS) criteria > 4, and EUS-fine needle aspiration (FNA) were included. A pseudotumor was defined as a non-neoplastic space-occupying lesion, a cause of chronic pancreatitis that may mimic changes typical of pancreatic cancer on CT or endoscopic ultrasound but without histological evidence. A real tumor was defined as a neoplastic space-occupying lesion because of pancreatic cancer confirmed by histology. Results: thirty-five patients with chronic pancreatitis were included, 26 (74.2%) of whom were men. Nine (25.7%) patients were diagnosed with PCP and two (2/35; 5.7%) patients with PCP were diagnosed with pancreatic cancer on follow-up. The time between the diagnosis of PCP and pancreatic adenocarcinoma was 35 and 30 days in the two patients. Definitive diagnosis of pancreatic adenocarcinoma was made by surgery. In the remaining six patients with PCP, the median of follow-up was 11 months (range 1–22 months) and they showed no evidence of malignancy on surveillance. In the follow-up of patients without PCP but with chronic pancreatitis, none were diagnosed with pancreatic cancer. According to our data, older patients with chronic pancreatitis are at risk of PCP. Conclusion: according to characteristics of patient, detection of PCP should lead a surveillance program for pancreatic cancer with EUS-FNA in < 1 month or directly to surgical resection. Core tip: actually, there are no clear recommendations for follow-up of patients with chronic pancreatitis and solid pancreatic mass lesions. We followed-up patients with chronic pancreatitis and solid pancreatic mass lesions and we assessed the final outcome and identified an optimal surveillance interval. We found that almost one-third of patients with chronic pancreatitis had PCP, and 22.2% had unresectable pancreatic adenocarcinoma less than 2 mo after the initial diagnosis. Endoscopic ultrasound fine needle aspiration can miss malignancy in nearly 25% of patients with PCP.

Characteristics of growth factors in the blood allowing determination of neuroendocrine component in pancreatic diseases.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16693-e16693
Author(s):  
Elena M. Frantsiyants ◽  
Irina V. Kaplieva ◽  
Ekaterina I. Surikova ◽  
Irina V. Neskubina ◽  
Valeria A. Bandovkina ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Growth Factors ◽  
Pancreatic Adenocarcinoma ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Pancreatic Disease ◽  
Standard Test ◽  
Blood Levels ◽  
Cancer Pathogenesis ◽  
Igf I

e16693 Background: Insulin-like growth factors I and II (IGF-I and II), transforming growth factor β (TGFβ) and its receptor (TGFβR2) are involved in cancer pathogenesis. At the same time, the features of these parameters in the blood related to the disease nature have yet to be determined. The purpose of the study was to analyze the dynamics of IGF-I, IGF-II, TGFβ and TGFβR2 in the blood of patients with pancreatic cancer. Methods: The study included male patients with pancreatic adenocarcinoma T1-3N0-1M0 (A, n = 18), pancreatic neuroendocrine tumors (NET, n = 12) and pancreatic adenocarcinoma with the neuroendocrine component T1-3N0-1M0 (A+NEC, n = 12) before the treatment. Healthy males (n = 21) were controls. Blood levels of IGF-I and IGF-II were measured by ELISA using standard test systems (Meddiagnost, Germany), as well as levels of TGFβ (BenderMedSystem, Austria) and TGFβR2 (RayBiotech, USA). Results: Patients with pancreatic cancer showed increased blood levels of IGF-II: in PA – by 1.9 times (p˂0.05), in NET – by 2.7 times and in A+NEC – by 3.4 times compared to values in healthy donors. TGFβ was elevated only in patients with A by 1.5 times (p˂0.05). TGFβR2 in the blood of patients with NET and A+NEC was increased by 4.8 and 4.5 times respectively, while in patients with A it was similar to control values. The TGFβ/TGFβR2 ratio was calculated; A+NEC was prognosed in patients with its level of 1.32±0.2. Conclusions: High blood levels of IGF-II were registered in patients with pancreatic cancer. The TGFβ/TGFβR2 ratio served as informative laboratory tests to predict the nature of pancreatic disease.

Prooxidant effect of α-tocopherol in pancreatic tumors.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16698-e16698
Author(s):  
Ekaterina I. Surikova ◽  
Elena M. Frantsiyants ◽  
Irina A. Goroshinskaya ◽  
Vladimir S. Trifanov ◽  
Viacheslav A. Aleynov ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neuroendocrine Tumors ◽  
Serum Levels ◽  
Pancreatic Tumors ◽  
Blood Levels ◽  
Biochemical Method ◽  
Diene Conjugates ◽  
Prooxidant Effect ◽  
Study Results ◽  
Mixed Tumors

e16698 Background: The coexistence of neuroendocrine tumors and pancreatic adenocarcinoma is rare, and treatment of such mixed tumors is challenging due to the differences in their natural course and response to systemic therapy. There is growing evidence that vitamins affect the biology of pancreatic tumors. The purpose of the study was to measure concentrations of retinol (RET), α-tocopherol (α-TCP) and diene conjugates (DC) in the blood of patients with pancreatic cancer in order to reveal its pathogenetic characteristics. Methods: Blood levels of RET and α-TCP (ELISA methods, Cloud-Clone Corp, USA), their ratio and DC concentrations (biochemical method) were measured before treatment if 42 patients with pancreatic cancer: adenocarcinoma (AC), T1-3N0-1M0, n = 9; AC with a neuroendocrine component (AC+NE) (up to 30%), n = 21; neuroendocrine tumors (NET), T1-3N0-1M0, n = 12. 22 healthy men of similar age were controls. All patients gave their voluntary informed consent for the study. Results: RET levels in all patient were statistically significantly lower than in controls: in AC by 3.8 times, in AC+NE by 1.9 times, in NET by 3.7 times (p = 0.0000). Concentrations of α-TCP in AC were 1.6 times (p = 0.0011) lower than in controls, in AC+NE were similar, and in NET α-TCP was 1.5 times higher than in controls (p = 0.0000). The ratio of α-TCP/RET in all patients significantly exceeded control values: in AC by 2.2 times, in AC+NE by 1.6 times, in NET by 5.7 times (p = 0.0000). Levels of DC in all patients were higher than in controls: in AC by 2.5, in AC+NE by 2.1, in NET by 2.7 times (p = 0.0001). Conclusions: Changes in serum levels of RET and α-TCP differ in patients with AC, NET and mixed tumors, which causes changes in the balance of vitamins and can contribute to a prooxidant effect, as evidenced by an increase in DC levels.

Blood levels of steroid hormone precursors allow differentiation between pancreatic adenocarcinoma and neuroendocrine tumors.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16692-e16692
Author(s):  
Viacheslav A. Aleynov ◽  
Elena M. Frantsiyants ◽  
Valeria A. Bandovkina ◽  
Natalia D. Cheryarina ◽  
Vladimir S. Trifanov ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Neuroendocrine Tumors ◽  
Steroid Hormone ◽  
Pancreatic Disease ◽  
Blood Levels ◽  
Pancreatic Cancers ◽  
Healthy Donors ◽  
Tumor Tissues ◽  
Study Results ◽  
Examination Methods

e16692 Background: The activity of some enzymes involved in the synthesis and transformation of sex hormones changes in some tumor tissues of the pancreas, which can affect the circulating concentrations of these hormones in the blood. The purpose of the study was to determine the possibility of differential diagnosis of pancreatic cancer at primary examination. Methods: Levels of 17OHP and DHEAS were measured by RIA in the blood of 25 men with chronic pancreatitis (CP), 34 patients with pancreatic adenocarcinoma (PA) and 15 patients with pancreatic neuroendocrine tumors (PNET). The results were compared with the levels in 23 healthy donors. All patients gave voluntary informed consent for the study. Results: Men with CP did not show statistically significant changes in 17OHP and DHEAS. The levels in pancreatic cancers were lower than in donors: in PA, DHEAS was 1.6 times and 17OHP - 1.4 times lower than the norm. DHEAS in PNET was 2.4 times lower than the norm and 1.5 times lower than in PA. 17OHP in PNET was 6.4 and 4.5 times lower, respectively. Conclusions: Measuring DHEAS and 17OHP in the blood can serve as an informative laboratory test for predictor assessment of the nature of pancreatic disease.

scholarly journals Expression patterns and prognostic values of the cyclin-dependent kinase 1 and cyclin A2 gene cluster in pancreatic adenocarcinoma

2020 ◽  
Vol 48 (12) ◽  
pp. 030006052093011
Author(s):  
Peng Jiang ◽  
Ming Zhang ◽  
Liangliang Gui ◽  
Kai Zhang
Keyword(s):  
Pancreatic Cancer ◽  
Pancreatic Adenocarcinoma ◽  
Malignant Tumors ◽  
Expression Patterns ◽  
Advanced Tumor Stage ◽  
Tissue Samples ◽  
Expression Levels ◽  
Kaplan Meier ◽  
Advanced Tumor ◽  
Kaplan Meier Plotter

Objective Pancreatic adenocarcinoma (PAAD) is one of the most lethal malignant tumors worldwide. Various studies based on cell lines, preclinical mouse models, and human tissue samples have shown that cell cycle-associated proteins are involved in the tumorigenesis and progression of PAAD. Methods Herein, we analyzed the relationships between CDK1 and CCNA2 gene expression and prognosis in patients with pancreatic cancer, using information from the Oncomine, cBioportal, Kaplan–Meier Plotter, and GEPIA databases. Results Expression levels of CDK1 and CCNA2 were significantly higher in PAAD compared with control tissues, and were associated with more advanced tumor stage. Survival analyses using the Kaplan–Meier Plotter database further confirmed that increased expression levels of CDK1 and CCNA2 were associated with a poor prognosis in patients with pancreatic cancer. Conclusions The results of this study suggest that CDK1 and CCNA2 may be potential therapeutic targets and prognostic biomarkers in patients with PAAD.

Sign in / Sign up

Export Citation Format

Share Document